Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian (Europe)
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian (Europe)
Rachel Reeves row : lettings agency takes blame for failing to get licence
30/10/2025
Government rules out public inquiry into Birmingham pub bombings
30/10/2025
Researchers discover new tyrannosaur species in ‘duelling dinosaurs’ fossil
30/10/2025
Will the real De Blasio please stand up ? A lesson from a UK newspaper’s gaffe
30/10/2025
Want to know what’s really up with Britain ? Take a look at our no-longer-chocolatey biscuits | Zoe Williams
30/10/2025
Walton : Cello Concerto, Symphony No 1, Scapino album review – positively snaps, crackles and pops
30/10/2025